Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd. (2186)

Market Closed
17 Jul, 08:00
HKEX HKEX
2. 06
HKD
-0.16
-7.2072%
HKD
9.59B Market Cap
- P/E Ratio
- Div Yield
67.91M Volume
- Eps
2.22 HKD
Previous Close
Add Transaction
Day Range
2.04 2.21
Year Range
1.73 4.49
Want to track 2186 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

2186 closed yesterday lower at 2.06 HKD, a decrease of -7.2072% from Thursday's close, completing a monthly decrease of -6.3636% or -0.14 HKD. Over the past 12 months, 2186 stock lost -24.8175%.
2186 is not paying dividends to its shareholders.
The last earnings report, released on Mar 27, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on HKEX (HKD).

2186 Chart

People also search for

Carsgen Therapeutics Holdings Limited
15.98 HKD
-6.4403%
Beijing Biostar Pharmaceuticals, Co., Ltd.
3.69 HKD
-0.2703%
Aim Vaccine Co. Ltd.
1.52 HKD
-5.5901%
CK Life Sciences Int'l.,
0.58 HKD
-1.6949%
Chervon Holdings Ltd.
19.06 HKD
+0.7932%

Luye Pharma Group Ltd. (2186) FAQ

What is the stock price today?

The current price is 2.06 HKD.

On which exchange is it traded?

Luye Pharma Group Ltd. is listed on HKEX.

What is its stock symbol?

The ticker symbol is 2186.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 9.59B.

Has Luye Pharma Group Ltd. ever had a stock split?

No, there has never been a stock split.

Luye Pharma Group Ltd. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
Mr. Dian Bo Liu CEO
HKEX Exchange
G57007109 CUSIP
DE Country
5,115 Employees
- Last Dividend
- Last Split
- IPO Date
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; and Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; research and development of antibody drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Contact Information

Address: No. 15 Chuang Ye Road, Yantai, China, 264003
Phone: -